#Empagliflozin treatment effects across categories of baseline #HbA1c, body #weight and blood #pressure as an add‐on to metformin in patients with type 2 diabetes

In EMPA‐REG MET, in patients with type 2 diabetes mellitus (T2DM) on stable background metformin (≥1500 mg/day), empagliflozin versus placebo significantly improved glycated haemoglobin (HbA1c), body weight (BW), and systolic blood pressure (SBP) over 24 and ≤76 weeks. This analysis investigated empagliflozin treatment effects by baseline cardio‐metabolic factors.. ..In total, 637 patients (56.7% males; mean [SD] age 55.7 [9.9] years, HbA1c 7.9 [0.9] %, BW 81.2 … Continue reading #Empagliflozin treatment effects across categories of baseline #HbA1c, body #weight and blood #pressure as an add‐on to metformin in patients with type 2 diabetes

#BMI and All‐Cause #Mortality in a Population‐Based Cohort in Rural South Africa

..The cohort consisted of 9,728 individuals. In adjusted models, those with BMI of 25.0 to 29.9 kg/m2 or 30.0 to 34.9 kg/m2 had a lower hazard of death (adjusted hazard ratio: 0.80; 95% CI: 0.69‐0.92 and adjusted hazard ratio: 0.75; 95% CI: 0.60‐0.93, respectively) compared with those with BMI of 18.5 to 24.9 kg/m2. Conclusions Individuals in South Africa who meet clinically defined criteria for … Continue reading #BMI and All‐Cause #Mortality in a Population‐Based Cohort in Rural South Africa